|
GB8529014D0
(en)
|
1985-11-25 |
1986-01-02 |
Biogen Nv |
Enhanced secretion of heterologous proteins
|
|
WO1987005330A1
(en)
|
1986-03-07 |
1987-09-11 |
Michel Louis Eugene Bergh |
Method for enhancing glycoprotein stability
|
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5571714A
(en)
|
1988-12-22 |
1996-11-05 |
Celtrix Pharmaceuticals, Inc. |
Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
|
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
|
ZA914750B
(en)
|
1990-06-20 |
1992-03-25 |
Bristol Myers Squibb Co |
Methods of modulating blood pressure using tgf-beta and antagonists thereof
|
|
GB9106678D0
(en)
|
1991-03-28 |
1991-05-15 |
Ferguson Mark W J |
Wound healing
|
|
US6008011A
(en)
|
1991-10-31 |
1999-12-28 |
Whitehead Institute For Biomedical Research |
TGF-β type II receptor cDNAs
|
|
JP4124815B2
(ja)
|
1991-10-31 |
2008-07-23 |
ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ |
ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
|
|
US5543143A
(en)
|
1992-03-06 |
1996-08-06 |
Corixa Corporation |
Method for activating macrophages/monocytes
|
|
JPH08504763A
(ja)
|
1992-10-29 |
1996-05-21 |
セルトリックス ファーマシューティカルズ，インコーポレイテッド |
治療薬としてのＴＧＦ−βレセプターフラグメントの使用
|
|
US5677196A
(en)
|
1993-05-18 |
1997-10-14 |
University Of Utah Research Foundation |
Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
|
ATE355369T1
(de)
|
1993-10-14 |
2006-03-15 |
Harvard College |
Verfahren zur induzierung und zur erhaltung neuronalen zellen
|
|
US5470952A
(en)
|
1993-10-20 |
1995-11-28 |
Regeneron Pharmaceuticals, Inc. |
CNTF and IL-6 antagonists
|
|
US5525490A
(en)
|
1994-03-29 |
1996-06-11 |
Onyx Pharmaceuticals, Inc. |
Reverse two-hybrid method
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
US5814565A
(en)
|
1995-02-23 |
1998-09-29 |
University Of Utah Research Foundation |
Integrated optic waveguide immunosensor
|
|
US5866323A
(en)
|
1995-04-07 |
1999-02-02 |
Case Western Reserve University |
Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
|
|
JPH11502717A
(ja)
|
1995-04-11 |
1999-03-09 |
ザ ジェネラル ホスピタル コーポレーション |
逆ツーハイブリッドシステム
|
|
US6423501B2
(en)
|
1996-12-13 |
2002-07-23 |
Beth Israel Deaconess Medical Center |
Calcium-independent negative regulation by CD81 of receptor signaling
|
|
AU737106B2
(en)
|
1997-04-18 |
2001-08-09 |
Biogen, Inc. |
Type II TGF-beta receptor/immunoglobulin constant region fusion proteins
|
|
WO1998047531A2
(en)
|
1997-04-21 |
1998-10-29 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
|
|
US6294350B1
(en)
|
1997-06-05 |
2001-09-25 |
Dalhousie University |
Methods for treating fibroproliferative diseases
|
|
ZA988461B
(en)
|
1997-09-18 |
1999-03-30 |
Idec Pharma Corp |
Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
|
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
CA2330939A1
(en)
|
1998-06-16 |
1999-12-23 |
Biogen, Inc. |
Variant type ii tgf-beta receptor fusion proteins and methods
|
|
ES2146552B1
(es)
|
1998-11-24 |
2001-04-16 |
Inst Cientifico Tecnol Navarra |
Peptidos inhibidores de tgf/31
|
|
DK1263464T3
(da)
|
2000-03-09 |
2013-01-28 |
Genzyme Corp |
Anvendelse af antagonist anti-TGF-BETA-antistoffer til behandling eller til forebyggelse af tab af nyrefunktion
|
|
WO2001073128A1
(en)
|
2000-03-24 |
2001-10-04 |
Dzgenes, Llc |
DIAGNOSTIC POLYMORPHISMS OF TGF-β-RII PROMOTER
|
|
US20030028905A1
(en)
|
2001-07-31 |
2003-02-06 |
Petra Knaus |
Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
|
|
US20030180301A1
(en)
|
2002-01-22 |
2003-09-25 |
Shaf Keshavjee |
Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
|
|
US7919084B2
(en)
|
2002-06-17 |
2011-04-05 |
St. Vincent's Hospital Sydney Limited |
Methods of diagnosis, prognosis and treatment of cardiovascular disease
|
|
AU2003297460A1
(en)
|
2002-12-19 |
2004-07-14 |
Scios, Inc. |
TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS
|
|
JP2006525362A
(ja)
|
2003-04-30 |
2006-11-09 |
ジェンザイム コーポレーション |
腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
NZ545544A
(en)
|
2003-08-13 |
2009-04-30 |
Univ Illinois |
Silencing of TGF-beta receptor type II expression by sirna
|
|
EP1658060A2
(en)
|
2003-08-22 |
2006-05-24 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Methods of treating copd and pulmonary hypertension
|
|
WO2005113585A2
(en)
|
2004-05-20 |
2005-12-01 |
Acceleron Pharma Inc. |
Modified tgf-beta superfamily polypeptides
|
|
US7786261B2
(en)
|
2004-09-02 |
2010-08-31 |
National Research Council Of Canada |
Coiled-coil fusion proteins comprising cell receptor domains
|
|
BRPI0515588A
(pt)
|
2004-09-22 |
2008-07-29 |
Genzyme Corp |
uso de antagonistas de tgf-beta para limitar a nefrotoxicidade de agentes imunossupressivos
|
|
US7795389B2
(en)
|
2004-09-28 |
2010-09-14 |
The Board Of Regents Of The University Of Texas System |
Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
|
|
US20090004182A1
(en)
|
2004-10-13 |
2009-01-01 |
The Ohio State University Research Foundation |
Methods to Treat or Prevent Viral-Associated Lymphoproliferative Disorders
|
|
CA2597098C
(en)
|
2005-02-08 |
2016-08-02 |
Steven R. Ledbetter |
Antibodies to tgfbeta
|
|
JP5342834B2
(ja)
|
2008-09-05 |
2013-11-13 |
日東電工株式会社 |
骨髄線維症処置剤
|
|
ITMI20060181A1
(it)
|
2006-02-03 |
2007-08-04 |
Univ Padova |
Modulatori del tgf-b e loro uso
|
|
US8454952B2
(en)
|
2006-03-13 |
2013-06-04 |
The Johns Hopkins University |
Augmentation of endothelial thromboresistance
|
|
JP2009539842A
(ja)
|
2006-06-05 |
2009-11-19 |
ノバルティス アクチエンゲゼルシャフト |
副甲状腺関連障害の処置におけるＴＧＦ−βアンタゴニストの使用
|
|
US8642034B2
(en)
|
2006-10-03 |
2014-02-04 |
Genzyme Corporation |
Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia
|
|
EP2578684B1
(en)
|
2007-03-19 |
2016-02-24 |
National Research Council Of Canada |
Antagonists of ligands and uses thereof
|
|
EP2171062A1
(en)
|
2007-06-15 |
2010-04-07 |
Genzyme Corporation |
Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
|
|
KR101171488B1
(ko)
|
2007-08-22 |
2012-08-07 |
아이알엠 엘엘씨 |
키나제 억제제로서의 2-헤테로아릴아미노-피리미딘 유도체
|
|
US20110245107A1
(en)
|
2008-01-18 |
2011-10-06 |
The Brigham And Women's Hospital, Inc. |
Selective differentiation, identification, amd modulation of human th17 cells
|
|
US8658135B2
(en)
|
2008-03-19 |
2014-02-25 |
National Research Council Of Canada |
Antagonists of ligands and uses thereof
|
|
WO2009143309A2
(en)
|
2008-05-21 |
2009-11-26 |
Trustees Of Dartmouth College |
Female reproductive tract and anal prophylaxes
|
|
WO2009152610A1
(en)
|
2008-06-20 |
2009-12-23 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
|
|
WO2010003118A1
(en)
|
2008-07-02 |
2010-01-07 |
Trubion Pharmaceuticals, Inc. |
Tgf-b antagonist multi-target binding proteins
|
|
US20120010178A1
(en)
|
2008-10-21 |
2012-01-12 |
President And Fellows Of Harvard College |
Methods and compounds for treatment of neurodegenerative disorders
|
|
EP2387412A4
(en)
|
2009-01-13 |
2013-04-03 |
Acceleron Pharma Inc |
METHODS FOR INCREASING ADIPONECTIN
|
|
US20120114640A1
(en)
|
2009-05-08 |
2012-05-10 |
Kulkarni Ashok B |
MODULATION OF THE TGF- ß AND PI3K/AKT PATHWAYS IN THE DIAGNOSIS AND TREATMENT OF SQUAMOUS CELL CARCINOMA
|
|
EP2524038A4
(en)
|
2010-01-12 |
2013-11-20 |
Isis Pharmaceuticals Inc |
MODULATION OF TRANSFORMING A GROWTH FACTOR BETA-1 EXPRESSION
|
|
IL300733A
(en)
*
|
2010-03-05 |
2023-04-01 |
Univ Johns Hopkins |
Compositions and methods for antibodies and fusion proteins targeting immune modulation
|
|
CN101852804B
(zh)
|
2010-03-29 |
2013-06-12 |
中国医学科学院病原生物学研究所 |
Gdf15蛋白的抗体的新用途
|
|
US8080568B1
(en)
|
2010-06-29 |
2011-12-20 |
Ewha University - Industry Collaboration Foundation |
2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
|
|
RU2637088C2
(ru)
|
2010-09-01 |
2017-11-29 |
Джензим Корпорейшн |
Лечение инфаркта миокарда с использованием антагонистов tgf-бета
|
|
US20130287688A1
(en)
|
2010-11-18 |
2013-10-31 |
Xtuit Pharmaceuticals, Inc. |
Novel compositions and uses of anti-hypertension agents for cancer therapy
|
|
US8800906B2
(en)
|
2010-12-27 |
2014-08-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Use of transforming growth factor-beta neutralizing antibodies and fusion proteins thereof in treating pain
|
|
SG191762A1
(en)
|
2011-01-06 |
2013-08-30 |
Glaxo Group Ltd |
Ligands that bind tgf-beta receptor ii
|
|
AU2012245491C1
(en)
*
|
2011-04-19 |
2017-12-21 |
Merrimack Pharmaceuticals, Inc. |
Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
|
|
CN108178789B
(zh)
|
2011-04-20 |
2021-11-02 |
阿塞勒隆制药公司 |
内皮糖蛋白多肽及其用途
|
|
CN102850458B
(zh)
|
2011-06-28 |
2014-10-01 |
华博生物医药技术（上海）有限公司 |
新型重组双功能融合蛋白及其制法和用途
|
|
WO2013012648A1
(en)
|
2011-07-15 |
2013-01-24 |
Emory University |
Gdf15 in diagnostic and therapeutic applications
|
|
CA2843535C
(en)
|
2011-08-01 |
2021-04-06 |
Tufts Medical Center, Inc. |
Treatment of cardiac diseases and fibrosis with endoglin receptor antibodies and antigen-binding fragments thereof
|
|
AU2013202269A1
(en)
|
2011-10-26 |
2013-05-16 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Compositions and methods for the treatment of fibrosis and fibrotic diseases
|
|
MY174248A
(en)
|
2012-04-30 |
2020-04-01 |
Biocon Ltd |
Targeted/immunomodulatory fusion proteins and methods for making same
|
|
US20150080320A1
(en)
|
2012-05-16 |
2015-03-19 |
Aadigen, Llc |
Multi-target modulation for treating fibrosis and inflammatory conditions
|
|
UY35384A
(es)
|
2013-03-11 |
2014-10-31 |
Genzyme Corp |
Anticuerpos y fragmentos de unión a antígeno diseñados para unirse al factor de crecimiento transformante ß (TGFß).
|
|
PT2970512T
(pt)
|
2013-03-12 |
2019-01-17 |
Biocon Ltd |
Proteínas de fusão imunomoduladoras e métodos para produção das mesmas
|
|
EP3470423B1
(en)
|
2013-04-17 |
2021-10-06 |
Baylor College of Medicine |
Immunosuppressive tgf-beta signal converter
|
|
EP3705498A1
(en)
*
|
2013-08-22 |
2020-09-09 |
Acceleron Pharma Inc. |
Tgf-beta receptor type ii variants and uses thereof
|
|
CA2931309C
(en)
|
2013-11-21 |
2022-06-21 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for treating pulmonary hypertension
|
|
SG10202108879SA
(en)
*
|
2014-02-10 |
2021-09-29 |
Merck Patent Gmbh |
TARGETED TGFβ INHIBITION
|
|
US10624929B2
(en)
|
2014-05-18 |
2020-04-21 |
Children's Medical Center Corporation |
Methods and compositions relating to exosomes
|
|
BR112016028833A2
(pt)
|
2014-06-13 |
2017-08-22 |
Novartis Ag |
uso de serelaxinaa para reduzir gdf-15
|
|
CN106794233B
(zh)
|
2014-08-01 |
2021-11-12 |
布里格姆及妇女医院股份有限公司 |
与肺动脉高压的治疗有关的组合物和方法
|
|
JP6631865B2
(ja)
*
|
2014-08-11 |
2020-01-15 |
日本化薬株式会社 |
ＴＧＦβ阻害機能を持つキメラタンパク質
|
|
MA53400A
(fr)
|
2015-04-06 |
2021-08-04 |
Acceleron Pharma Inc |
Hétéromultimères alk7: actriib et leurs utilisations
|
|
KR20170141215A
(ko)
|
2015-04-06 |
2017-12-22 |
악셀레론 파마 인코포레이티드 |
싱글-암 유형 i과 유형 ii 수용체 융합 단백질들 및 이들의 용도
|
|
US9884900B2
(en)
|
2015-08-04 |
2018-02-06 |
Acceleron Pharma Inc. |
Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor
|
|
CA2996996A1
(en)
|
2015-08-31 |
2017-03-09 |
National Research Council Of Canada |
Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
|
|
WO2017134592A1
(en)
|
2016-02-03 |
2017-08-10 |
Biocon Limited |
Anti-cd20/immunomodulatory fusion proteins and methods for making same
|
|
IL264730B1
(en)
|
2016-08-12 |
2024-05-01 |
Merck Patent Gmbh |
A pharmaceutical preparation containing TGFbetaRII and another anti-cancer preparation
|
|
CA3038526A1
(en)
*
|
2016-09-27 |
2018-04-05 |
Epicentrx, Inc. |
Immunomodulatory fusion proteins
|
|
CA3048646A1
(en)
|
2017-01-07 |
2018-07-12 |
Merck Patent Gmbh |
Dosing regimens and dosage forms for targeted tgf-b inhibition
|
|
AU2018228435A1
(en)
|
2017-03-02 |
2019-10-03 |
National Research Council Of Canada |
TGF-beta-receptor ectodomain fusion molecules and uses thereof
|
|
US20220211805A1
(en)
|
2018-02-09 |
2022-07-07 |
Acceleron Pharma Inc. |
Methods for treating heterotopic ossification
|